Damage in systemic lupus erythematosus and its association with corticosteroids
Top Cited Papers
Open Access
- 1 August 2000
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 43 (8) , 1801-1808
- https://doi.org/10.1002/1529-0131(200008)43:8<1801::aid-anr16>3.0.co;2-o
Abstract
Objective To evaluate the association between corticosteroid use and organ damage in patients with systemic lupus erythematosus (SLE). Methods The occurrence and date of organ damage, as measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, were determined for 539 patients enrolled in the Hopkins Lupus Cohort Study. The risk of damage associated with the cumulative prednisone dose, high‐dose prednisone (≥60 mg/day for ≥2 months), and pulse methylprednisolone (1,000 mg intravenously for 1–3 days) was estimated using Cox proportional hazards regression analyses, controlling for age, race, and sex. Risk estimates for the cumulative prednisone dose were based on a reference dose of 36.5 gm (e.g., 10 mg of prednisone daily for 10 years [or equivalent]). Results The cumulative prednisone dose was significantly associated with the development of osteoporotic fractures (relative risk [RR] 2.5, 95% confidence interval [95% CI] 1.7, 3.7), symptomatic coronary artery disease (RR 1.7, 95% CI 1.1, 2.5), and cataracts (RR 1.9, 95% CI 1.4, 2.5). Each intravenous pulse was associated with a small increase in the risk of osteoporotic fractures (RR 1.3, 95% CI 1.0, 1.8); however, this result failed to reach statistical significance (P = 0.07). Each 2‐month exposure to high‐dose prednisone was associated with a 1.2‐fold increase in the risk of both avascular necrosis (95% CI 1.1, 1.4) and stroke (95% CI 1.0, 1.5). Conclusion SLE patients receiving long‐term prednisone therapy were at significant risk of morbidity due to permanent organ damage. Additional research is required to determine the relative contributions of SLE disease activity and corticosteroids to the pathogenesis of specific types of organ damage. Furthermore, new steroid‐sparing therapies are needed in order to treat disease activity and minimize cumulative and high‐dose prednisone exposure.Keywords
This publication has 30 references indexed in Scilit:
- Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease durationLupus, 1998
- The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosusArthritis & Rheumatism, 1997
- SLICC/ACR DAMAGE INDEX IS VALID, AND RENAL AND PULMONARY ORGAN SCORES ARE PREDICTORS OF SEVERE OUTCOME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSRheumatology, 1996
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- TRABECULAR AND CORTICAL BONE LOSS IN SYSTEMIC LUPUS ERYTHEMATOSUSRheumatology, 1996
- Musculoskeletal complications of systemic lupus erythematosus in the hopkins lupus cohort: An updateArthritis & Rheumatism, 1995
- THE EFFECT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND LONG-TERM STEROID THERAPY ON BONE MASS IN PRE-MENOPAUSAL WOMENRheumatology, 1995
- Loss of bone mineral density in premenopausal women with systemic lupus erythematosus.Annals of the Rheumatic Diseases, 1995
- Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry.Annals of the Rheumatic Diseases, 1990
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982